Clinical Trials
208 trialsNCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04030559 2026-05-14
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Terminated
NCT04631744 2026-05-01
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06630325 2026-04-28
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04984343 2026-04-23
FORT
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT02946996 2026-03-05
Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Medical University of South Carolina
Phase 2 Terminated
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05366842 2026-01-30
Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care
Johns Hopkins University
Phase 2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT05067777 2025-12-15
mPROSTATE
University of Utah
Phase 2 Terminated
NCT02772562 2025-12-12
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy
Medical University of South Carolina
Phase 2 Terminated
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT04635059 2025-11-17
BLAST
Medical College of Wisconsin
Phase 2 Terminated
NCT04616547 2025-10-03
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
National Cancer Institute (NCI)
Phase 2 Terminated
NCT03432897 2025-07-08
337
Brown University
Phase 2 Terminated
NCT04102124 2025-06-24
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT05712174 2025-06-12
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
AHS Cancer Control Alberta
Phase 2 Terminated
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT05177770 2025-05-08
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Coherus Oncology, Inc.
Phase 2 Terminated
NCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT04383210 2025-04-03
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
Phase 2 Terminated
NCT04298983 2025-03-19
RAD 1805
University of Alabama at Birmingham
Phase 2 Terminated
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT03152786 2025-02-17
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Wake Forest University Health Sciences
Phase 2 Terminated
NCT05501548 2025-01-29
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04159896 2024-07-16
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT03690141 2024-06-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Effector Therapeutics
Phase 2 Terminated
NCT01393119 2024-04-22
Phase II, Dose Finding Study of GTx-758
GTx
Phase 2 Terminated
NCT03810105 2024-04-09
A Study of Olaparib and Durvalumab in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02933801 2024-03-13
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Swiss Cancer Institute
Phase 2 Terminated
NCT03533946 2024-03-13
ROAR
University of Utah
Phase 2 Terminated
NCT00019695 2024-03-04
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04727736 2024-02-15
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
University of Pittsburgh
Phase 2 Terminated
NCT04264208 2024-02-01
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Stanford University
Phase 2 Terminated
NCT01996696 2024-01-30
PREMIUM
AHS Cancer Control Alberta
Phase 2 Terminated
NCT00176631 2023-12-22
Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01420861 2023-10-06
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
GTx
Phase 2 Terminated
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT01377389 2023-09-29
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03999515 2023-09-28
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
University of Washington
Phase 2 Terminated
NCT00176644 2023-09-13
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00483561 2023-09-13
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
University of Nebraska
Phase 2 Terminated